CHROMID® VRE

Chromogenic medium for screening of Vancomycin-Resistant Enterococci

Specific and selective chromogenic medium for the detection and differentiation of Enterococcus faecium and E. faecalis showing acquired Vancomycin resistance (VRE).

  • Specific coloration for easy-to-read, clear differentiation of E. faecium & E. faecalis
  • Isolation & detection of VanA and VanB genotypes
  • Incubation in 24 hours
Add to your selection

Do you need more information?

Clear identification of VRE

bioMérieux’s CHROMID® VRE offers rapid, reliable screening of  Enterococcus faecalis and E. faecium with acquired Vancomycin resistance (VRE), multi-resistant bacteria that are increasingly involved in healthcare-associated infections (HAI). As with all products in the CHROMID® range, you gain the confidence of an easy to use, standardized method. The quality of CHROMID® decreases the number of confirmation tests, lowering workload, and saving time and costs. CHROMID® VRE contains two chromogenic substrates (α-glucosidase and β-galactosidase) and Vancomycin, which enable:

  • Direct identification of  E. faecalis and E. faecium
  • Specific and selective isolation and detection of acquired Vancomycin-Resistant enterococci (VRE) (VanA and VanB)
  • Differentiation of Vancomycin-resistant E. faecium and Vancomycin-resistant E. faecalis
  • Specific coloration makes differentiation easy:
    • Blue-green colonies: E. faecalis
    • Violet colonies: E. faecium
  • Selective mix inhibits:
    • Non-resistant enterococci
    • Enterococci with natural resistance (VanC)
    • Most Gram-negative and Gram-positive bacteria
    • Yeasts and molds

VRE: A major issue in healthcare-associated infections

Enterococci can cause dangerous infections for people who have weakened resistance, such as those who are immunocompromised or who have undergone surgery. The rise of enterococci that have developed resistance to Vancomycin, a “last-resort” antibiotic, is a particular concern for the fight against healthcare-associated infections (HAI). The Centers for Disease Control labelled Vancomycin-Resistant Enterococci (VRE) a “serious concern” in its Antibiotic resistance threats 2013 report, because about 30% of enterococci-related HAI in the US are Vancomycin-resistant. Infection with VRE leaves clinicians with few or no treatment options. Rapid and reliable detection of VRE enables timely implementation of appropriate treatment and infection control measures, important to fighting antimicrobial resistance and to containing HAI.

MDRO and HAI: Culture media to help fight

CHROMID® VRE is part of bioMérieux’s CHROMID® chromogenic media range for SMART antimicrobial resistance management. We designed this range to make it easy for you to access high-quality chromogenic media to help manage the serious healthcare challenges presented by antimicrobial resistance and healthcare associated infections (HAI).

Technical specifications: CHROMID® VRE

CHROMID® VRE Reference number Technical Specifications

43004

20 x 90 mm

CE marked product

  • Antibiotic resistance threats 2013
     
  • Cheng VC et al., Extensive contact tracing and screening to control the spread of vancomycin-resistant Enterococcus faecium ST414 in Hong Kong. Chinese Medical Journal 2012;125:3450-3457
     
  • Klare I et al., Performance of three chromogenic VRE screening agars, two ETEST® vancomycin protocols, and different microdilution methods in detecting vanB genotype Enterococcus faecium  with varying vancomycin MICs. Diagnostic Microbiology and Infectious Disease 2012;74:171–176

Please consult your local bioMérieux representative for product availability in your country

Pioneering diagnostics